Vaccinia virus (ATCC® VR-2047)

Classification: Poxviridae, Orthopoxvirus  /  Product Format: frozen

Classification Poxviridae, Orthopoxvirus
Agent Vaccinia virus
Strain vP-13
Biosafety Level 2

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Isolation
A HhaI fragment encoding HBsAg was cloned into vP-8 (ATCC VR-2053) by in vivo recombination. No expression of the insert has been detected.
Product Format frozen
Storage Conditions -70°C or colder
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Comments
Recombinant vaccinia containing the Hhal hepatitis B fragment coding for HBV surface antigen.
A HhaI fragment encoding HBsAg was cloned into vP-8 (ATCC VR-2053) by in vivo recombination. No expression of the insert has been detected.
Effect on Host
Yes, in vitro effects: Cytopathic effects in tissue culture
CPE.
Effect on Host
Yes, in vitro effects: Cytopathic effects in tissue culture
CPE.
Name of Depositor E Paoletti
U.S. Patent
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
References

Paoletti E, Panicali D. Modified vaccinia virus. US Patent 4,603,112 dated Jul 29 1986

Hammon WM, et al. Isolation and characterization of prototype viruses ECHO-26, ECHO-27, Coxsackie B-6. Proc. Soc. Exp. Biol. Med. 103: 164-168, 1960. PubMed: 14399342